Voranigo (vorasidenib)

pCPA File Number: 23394

Negotiation Status:

Active Negotiation

Indication(s):

For the treatment of Grade 2 WHO 2016, 2021 grading system astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.

Sponsor/Manufacturer:

Servier Canada Inc.

CDA-AMC Project Number:

PC0407-000

pCPA Engagement Letter Issued:

2025-12-16

Negotiation Process Concluded:

Not Applicable